1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene: a 5-HT2C agonist and 5-HT2A,2B antagonist; RN refers to (trans)-isomer; a phenylaminotetralin; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10015055 |
| CHEMBL ID | 3402679 |
| SCHEMBL ID | 3755417 |
| MeSH ID | M0225710 |
| Synonym |
|---|
| h2-pat |
| trans-4-phenyl-2-n,n-dimethylaminotetralin |
| 1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene |
| 152786-06-6 |
| trans-pat |
| gtpl1212 |
| (-)-trans-h2-pat |
| (2r,4s)-n,n-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine |
| PDSP2_000944 |
| PDSP1_000959 |
| SCHEMBL3755417 |
| trans-h2-pat(+) |
| bdbm86029 |
| CHEMBL3402679 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.4700 | 0.0001 | 1.4162 | 9.9000 | AID1193128 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.4700 | 0.0000 | 0.3855 | 10.0000 | AID1193128 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.4300 | 0.0001 | 0.9549 | 10.0000 | AID1193130 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.2400 | 0.0003 | 0.7693 | 10.0000 | AID1193129 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.0300 | 0.0001 | 0.3399 | 8.5110 | AID1193131 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||